secwatch.observer — SEC 8-K summary
======================================

Issuer:     CUMBERLAND PHARMACEUTICALS INC (CPIX)
CIK:        0001087294
Form:       8-K
Filed at:   2025-11-04T23:59:59+00:00
Accession:  0001087294-25-000017
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cumberland Pharma reports Q3 net loss of $1.9M; YTD revenue up 12% to $30.8M
----------------------------------------------------------------------------

- Net revenue for Q3 2025 was $8.3M; YTD $30.8M (+12% vs. 2024).
- Net loss Q3 $1.9M; YTD net loss $1.4M. Adjusted loss Q3 $0.8M ($0.06/sh); adjusted earnings YTD $1.9M ($0.13/sh).
- Added Talicia via joint venture with RedHill: Cumberland invests $4M for 30% ownership; net revenue split equally.
- Vibativ launched in Saudi Arabia; ibuprofen injection approved in Mexico; Vibativ available through Vizient.
- Ifetroban Phase II DMD showed 5.4% cardiac improvement; Phase II SSc enrollment complete; IPF trial enrolling.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1087294/000108729425000017/0001087294-25-000017-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1087294/000108729425000017/cpix-20251104.htm
  HTML page:      https://secwatch.observer/filing/0001087294-25-000017

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer